Nu.Q® Discover tools provide drug developers and scientists with a range of rapid epigenetic profiling assays across pre-clinical and clinical development pathways from discovery to market ready ...
HENDERSON, Nev., Feb. 6, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) Volition a multi-national epigenetics company, announces its first commercial sale of Volition's High Throughput ...
HENDERSON, Nev., Sept. 29, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has signed an agreement with ...
Volition's Nu.Q® Discover program enables drug developers and scientists access to a range of state-of-the-art assays for rapid epigenetic profiling in disease model development, preclinical testing, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback